DS45500853 is an estrogen-related receptor α ( ERRα ) agonist. DS45500853 inhibits the binding between receptor-interacting protein 140 (RIP140) corepressor peptide (10 nM) and GST-ERRα ligand-binding domain (LBD; 1.2 μM) with an IC 50 value of 0.80 μM. DS45500853 can be used for the research of metabolic disorders, including type 2 diabetes mellitus (T2DM) In Vitro DS45500853 (compound 5c; 0.002, 0.006, 0.017, 0.051, 0.015, 0.046, 1.4, 4.2, 12.5 μg/mL; 18 h) inhibits the transcriptional activity of full-length ERRα in MG63 cells with an EC 50 of 5.4 μM. DS45500853 binds in the ligand-binding pocket (LBP) of the ERRα LBD as inverse agonist II. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:ERRα